Introduction
Immunological responses following nonviral DNA delivery decrease the magnitude and duration of transgene expression, and reduce the effectiveness of frequent dosing. [1] [2] [3] [4] Unmethylated CpG motifs on plasmid DNA, 1 cationic lipid formulations, 2 and lipid/DNA lipoplexes [2] [3] [4] contribute to the deleterious immunological responses. The addition of free glucocorticoids to lipofection formulations has been shown to increase the transfection efficiency over lipoplexes alone by modulating the immunological response to gene delivery. 1, 5, 6 Although cationic lipids for lipofection condense plasmid, facilitate endosome escape, neutralize charge of DNA, and/or shield DNA from nucleases, 7 no pharmacologically active cationic lipids have been reported to possess anti-inflammatory activity.
We report a new approach to nonviral gene delivery that uses a novel, pharmacologically active cationic glucocorticoid. The rationale was to engineer gene delivery activity into an approved pharmaceutical agent as well as to develop a cost-effective and easily scaleable synthesis. Therefore, we conjugated dexamethasone, a potent glucocorticoid recognized to enhance transgene expression in vivo by its anti-inflammatory activities, 1, 6 with spermine via iminothiolane in a one-pot reaction to synthesize the dexamethasone-spermine (DS) conjugate. Reminiscent of the clinically relevant cationic lipids, 7 DC-Chol and CTAP, DS has the added functionality of glucocorticoids to improve gene delivery. To our knowledge, this is the first reported example of a cationic lipid that both displays pharmacological activity as well as facilitates DNA packaging and delivery.
Results

Synthesis of cationic dexamethasone
The 21-hydroxy group of dexamethasone is not required for anti-inflammatory activity, 8 and therefore is an ideal choice for conjugation to a polycation ( Figure 1a) . A onepot reaction between spermine, 2-iminothiolane (Traut's reagent) and dexamethasone mesylate yielded the DS conjugate, 1 as the major product (Figure 1b ). Traut's reagent is selectively ring-opened by the primary amines 9 on spermine, forming a hydrolytically sensitive amidine bond 9 between spermine and iminothiolane and a reactive thiolate anion that reacts with the a-keto mesylate on the 21 position of dexamethasone mesylate 10 to form an a-keto thioether between spermine and iminothiolane. The conjugation reaction was complete in 45 min by HPLC. 1 H NMR of DS (data not shown) confirmed the presence of the 3-bis-enone and 11-and 17-hydroxy groups required for glucocorticoid activity (Figure 1a) as well as 1 H signals from the conjugated spermine and the 21-a-keto thioether group. Hydrolysis of DS in 1 M NaOH for 20 min resulted in the cleavage of the amidine linkage between spermine and iminothiolane, forming 2, a dexamethasone-amide (DA) (Figure  1b ), which has a 21-substituted butyl thioether amide side chain on dexamethasone. For 2: Calc, C: 63.26; H: 7.35; N: 2.84; and Found, C: 63.44; H: 7.27; N: 2.83. Water solubility: DS4100 000 mg/l; DA 60 mg/l; (dexamethasone 100 mg/l).
In vitro gene delivery with cationic steroids
Using the neutral lipid dioleoylphosphatidylethanolamine (DOPE) and 1 mg plasmid/well, we measured the gene expression obtained with varying amounts of DS (0-20 mg) and varying amounts of DOPE (0-20 mg) (Figure 2a) . Lipofectamine was used (6 mg/mg DNA) as a benchmark. The mass ratio of 1:2 of DS:DOPE (yellow bars, Figure 2a ) provided a high EGFP expression, while minimizing the use of the DS conjugate and minimizing the total lipid load below 10 mg total lipid/mg DNA. In a separate set of experiments maintaining the DS:DOPE mass ratio constant at 1:2, the amount of DS relative to DNA was systematically varied from 1 to 10 charge equivalents (0.9 mg DS/mg DNA), assuming an average charge of the spermine of DS to be 3.8/molecule, 11 and no net charge contribution from DOPE. The optimal lipofection plateaued at a charge ratio of 6 DS:1 DNA, giving a more than 10-fold increase in the amount of transgene expression relative to Lipofectamine reagent. Increases beyond a charge ratio of 6:1 DS:DNA provided no further increase in expression (Figure 2b ). To test if gene transfer activity of DS was merely associated with the DNA-binding ability of spermine and the hydrophobic character of dexamethasone, we mixed DNA with spermine, dexamethasone, and DOPE (all unconjugated) using the same molar ratios and concentrations as in the conjugated DS/DOPE transfection ( Figure 2d ). Only when the dexamethasone was conjugated with spermine was EGFP expression detected ( Figure 2e) . Spermine alone or dexamethasone alone had no detectable gene transfer activity (data not shown). Using a flow cytometry cutoff of 100 FI to define percent transfection, 12 we observed a 4.3-fold increase in percent transfection over Lipofectamine from 5.9 to 25.5% ( Figure  3) . Lipofection of subconfluent (proliferating) BAEC with DS/DOPE yielded a 4.6-fold increase in percent transfection over Lipofectamine from 16.0% with Lipofectamine to 73.8% lipofection with DS/DOPE (data not shown). The amidine bond in DS appeared to be relatively stable in neutral pH when formulated with DOPE, since DS/ DOPE formulations stored for 6 months at 41C in water retained their lipofection activity.
Pharmacological activity of cationic steroid in vitro
The delivery of dexamethasone or DS/DOPE at 10-1000 nM, of steroid pharmacophore, caused rapid nuclear localization of a glucocorticoid-competent GFP-GR chimeric protein (Figure 4a ) stably expressed in 3T3 cells. As soon as 5 min after the addition of DS/DOPE cells, GFP-GR fluorescence increased within the nucleus with complete localization occurring in less than 1 h similar to the localization induced by dexamethasone. Partial nuclear import of GFP-GR by 10 nM DS/DOPE and complete nuclear import at 100 nM suggested that the effective K D for DS was approximately 10-fold higher than that of dexamethasone (K D B3 nM), 13 potentially due to reduced access to the cytosolic GR caused by endosome sequestration or association of DS with anionic elements in the cytosol. While nuclear localization of GR is one test of glucocorticoid activity, we also employed a second test of pharmacological activity, the ability to induce gene expression from a glucocorticoidresponsive promoter. DS induced dose-dependent transcription from a GRE promoter construct (pGRE-SEAP), displaying an EC 50 of B10-100 nM relative to dexamethasone in 293 cells. DS induced statistically significant levels of SEAP transcription from a GRE promoter at or above 100 nM concentrations. At high dose, DS may be a partial antagonist of corticosteroid-mediated transactivation of GRE promoters.
In vivo activity of DS in thioglycollate (TG) model of inflammation
Given the known benefits of using dexamethasone to enhance nonviral gene transfer in vivo, we designed experiments to address specifically the central issue of whether DS had anti-inflammatory activity. Male BALB/ c mice were pretreated with vehicle, dexamethasone (2 mg/kg), or an equimolar amount of DS (5.85 mg/kg), for 30 min prior to intraperitoneal (i.p.) TG challenge. At 4 h postchallenge, DS significantly (P ¼ 0.0058, n ¼ 6) inhibited the accumulation of neutrophils in the i.p. space versus vehicle (1% ethanol in phosphate-buffered saline (PBS)), resulting in a 60% reduction in neutrophil immigration ( Figure 5 ). Similar results were obtained with groups pretreated with dexamethasone or DS 48 h Cationic corticosteroid for gene delivery JA Gruneich et al prior to TG challenge (not shown). All animals remained healthy in all groups, indicating that DS at the tested dose was not lethal.
Mouse pulmonary DNA transfer
Having demonstrated the anti-inflammatory activity of DS at a relevant pharmacological dose (no DOPE present) in the TG challenge model, a set of experiments was conducted with lipoplexes to evaluate gene transfer activity and the anti-inflammatory action of DS. DC-Chol was chosen as a commercially available reference lipid since it is sterol-based and has been used in animal and human clinical trials and is commonly formulated with the neutral lipid DOPE. This avoids referencing DS:DOPE against other nonsterol cationic lipids used with cholesterol, for example, as the neutral lipid. At a molar ratio of cationic sterol lipid:DOPE:base of 1:1:1 used to deliver 100 mg of plasmid (50 ml intranasal instillation), DS:DOPE resulted in a statistically significant 64% reduction (P ¼ 0.08, n ¼ 4) of interferon-g (IFNg)/g of homogenized lung at Day 1 compared to DCChol:DOPE (Table 1) . DS lipoplexes resulted in less tumor necrosis factor-a (TNF-a) expression on average compared to DC-Chol lipoplexes at Day 1, but did not reach statistical significance in this small cohort study due to the high variability of TNF-a expression in the DC-Chol group. At Day 1, DS:DOPE resulted in a statistically significant increase of 3.22-fold (P ¼ 0.029) over DC-Chol:DOPE in the expression of the alkaline phosphatase (alk. phos.) transgene. At Day 7, one animal of the DS:DOPE cohort expressed 415 times more alk. phos. than the other three members of the cohort. By eliminating this overexpressor the DS:DOPE cohort resulted in a statistically significant 6.78-fold increase 
Discussion
Cationic prodrug vehicles for gene transfer represent an attractive approach for simultaneous local gene and drug delivery. Many pharmacologically active agents are hydrophobic and can be converted to cationic prodrugs using chemistries similar to those shown in Figure 1b . We used dexamethasone since it is a well-studied hydrophobic drug with potent immunomodulating effects and has a K D with GR of B3 nM. 8, 13 At the optimal in vitro formulation, at a charge ratio of 6:1 DS:DNA, each plasmid can deliver DS to a cell to result in about 30 nM final intracellular concentration of drug, well above the K D . Moreover, DS has anti-inflammatory activity in vivo and may be useful in its own right as a drug for inflammation, asthma, arthritis, or other inflammatory diseases.
Distinct from other approaches that conjugate steroid directly to oligonucleotides 14, 15 or plasmids, 16 the delivery of plasmid with DS resulted in pharmacologically relevant amounts of steroid inside each lipofected cell. It is unlikely that steroid covalently linked to DNA will allow the normal functioning of the glucocorticoid receptor, whereas DS activates nuclear translocation of GR and gene induction from a glucocorticoid response element (Figure 4 ). In addition, DS delivers DNA but is not conjugated to the DNA and therefore does not inactivate transcription of the transgene (Figure 2b ) as has been observed with the chemical conjugation of steroid 16 or classical NLS to DNA. In addition to its benefits as an anti-inflammatory agent (Figure 4) , DS serves as the cationic lipid itself for high efficiency transfection (Figure 3) , whereas chemical modification of DNA with steroid still requires the use of a cationic delivery vehicle. 16 Furthermore, the pharmacokinetic clearance of DS is expected to be markedly different from dexamethasone, thus providing a depot effect of the anti-inflammatory drug in the local tissue site of DNA administration, which cannot be achieved by simply adding dexamethasone to the lipoplex, or by systemic or local administration of dexamethasone.
The approach described here builds upon these known benefits of glucocorticoids to gene transfer 1, 5, 6 as well as providing evidence that DS conjugates are efficient gene delivery molecules themselves when used with DOPE. DS/DOPE/DNA lipoplexes resulted in 25.5 and 73.8% transfection (4.3-and 4.6-fold enhancement in percent transfection over Lipofectamine) in confluent and subconfluent BAEC, respectively (Figure 3) . DS was designed for broad applicability to nonviral gene delivery applications, except those requiring an Cationic corticosteroid for gene delivery JA Gruneich et al increased immune/inflammatory response (eg DNA vaccines). DS/DOPE for gene delivery may work well for diseases that show palliation by glucocorticoids such as asthma, arthritis, allergies, and other inflammatory diseases. Alternatively, the choice of pharmacophore could be made in conjunction with the selection of the transgene and the route of delivery to achieve a particular therapeutic effect.
Dexamethasone has been shown to help gene delivery by blocking inflammation and regulating the immune response to gene delivery. The major inflammatory cytokines upregulated after gene delivery are TNF-a, IL-1, IL-6, IL-12, and IFN-g, all of which are transrepressed by corticosteroids. A major cell type in initiating inflammation is the neutrophil, and DS worked as good as or better than dexamethasone to inhibit neutrophil immigration in a mouse model of inflammation ( Figure  5 ). In addition, DS also gives good gene delivery results in vitro relative to the standard gene delivery agent Lipofectamine. Therefore, DS may offer unique benefits to gene delivery in vivo because it both delivers DNA well and inhibits the inflammatory response that reduces the level and duration of transgene expression.
In vivo analysis of the anti-inflammatory activity of DS versus dexamethasone was performed with the i.p. injection of TG into mice ( Figure 5 ), since it is a simple model to implement for screening purposes, and because it is an injection into the body of the animal as opposed to topical application of the drug (eg sephadex-induced lung edema in the rat, or the mouse ear punch assay), thereby mimicking in vivo injection of DNA. Figure 5 illustrates that DS inhibits neutrophil immigration. Although the formulation of DS with DOPE and DNA may significantly alter its pharmacodynamics and pharmacokinetics, these data illustrate the proof of principal that DS has anti-inflammatory activity.
The intent of this study was to demonstrate that pharmacophores can be modified through one-step chemistries to become lipofection reagents that display in vitro pharmacological activity. We also demonstrated that this compound has anti-inflammatory action in two different animal models. While GL67 has a powerful gene transfer activity that exceeds DC-Chol in pulmonary gene transfer studies, 17 issues of toxicity persist. The potential exists to use DS in formulations with GL67 (or even with adenovirus) to reduce undesired inflammatory reactions. While DS:DOPE resulted in less IFN-g expression at Day 1 and higher transgene expression at Day 7 compared to DC-Chol:DOPE, it remains to be shown that the reduction of inflammation was the cause of the 46-fold increase in transgene expression at Day 7 (Table 1 ) seen with DS:DOPE. Such studies would require dexamethasone analogs lacking corticosteroid activity.
We note that for gene delivery applications, at an optimal in vitro charge ratio of 6:1 DS:DNA, each plasmid can deliver DS to a cell to result in about 30 nM final intracellular concentration of the drug, well above the K D . Hundreds to thousands of lipoplexes would deliver significantly more DS to each cell, while DS may be useful in its own right as a depot-like agent for inflammatory disease.
Materials and methods
Synthesis and hydrolysis of cationic steroids
Dexamethasone and dexamethasone mesylate (Steraloids, NH), Traut's reagent (Pierce), spermine (Sigma), and DMSO (Aldrich) were used as received. A total of 105 mg (223 mmol) of dexamethasone-mesylate, 800 ml of DMSO, and 28.4 mg (206 mmol) of Traut's reagent were dissolved together prior to the addition of 31.9 ml (145 mmol) of spermine at room temperature. After 45 min, the reaction was complete by TLC. HPLC purification (60/40 0.1%TFA/acetonitrile, Hamilton PRP-1 column) and freeze-drying yielded DS trifluoracetic acid salt as a white powder. Yield: 15.3 mg (14.0%). DA was isolated from hydrolyzed DS by semipreparative HPLC. For all studies using DS, DS was purified by semipreparative scale HPLC as a tetrafluoroacetate salt. DS had no contamination with free dexamethasone or dexamethasone mesylate, and less than 1% contamination with DA.
Cell culture and Lipofection
Bovine aortic endothelial cells (BAECs, passages [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] were passed at a 1:3 split to 24-well culture plates, and then grown to dense confluence before lipofection. The growth medium was Dulbeccos's modified Eagle's medium containing 10% heat-inactivated charcoal-filtered (to remove steroid hormones) fetal calf serum (Hyclone), 0.30 mg/ml glutamine, 150 U/ml penicillin, and 0.15 mg/ml streptomycin (Gibco). The 293 cells were grown under identical conditions. The plasmids pEGFP-N3 and pGRE-SEAP (Clontech) were used for the expression of EGFP or secreted alk. phosp. under the regulation of CMV or GRE promoters, respectively. Lipofectamine reagent (Gibco) containing 3:1 (mg:mg) mixture of polycationic lipid 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA):DOPE was used according to the manufacturer's instructions.
Preparation and characterization of lipid assemblies and lipoplexes
To form the DS:DOPE lipid solution, 67 ml of a 10 mg/ml solution of DS in ethanol and 27 ml of a 50 mg/ml 
Glucocorticoid receptor localization assay
The 3T3 cell line 3676 expressing green fluorescent protein-glucocorticoid receptor chimeric protein from a tetracycline-regulated promoter 18 was used to image GR receptor localization into the nucleus. Cells were maintained in growth media supplemented with 100 mg/ml geneticin. The cells were incubated for 30 min with dexamethasone or DS/DOPE ranging in concentration from 10 to 1000 nM, and nuclear translocation of GFP-GR was visualized at 40 Â using a Hamamatsu CCD camera and Leica DM IRBE fluorescent microscope.
Induction of transcription from GRE
The levels of GRE induction using DS/DOPE was compared with dexamethasone using a GRE-SEAP promoter construct assay (Clontech). The 293 cells were lipofected with GRE-SEAP plasmid in triplicate using 1 mg plasmid and 6 mg Lipofectamine per well in 24-well plates. After 120 min, the lipofection media were replaced with 500 ml of growth media, and the cells were treated with dexamethasone or DS/DOPE over a range from 1 to 10 000 nM. After 24 h of induction, 50 ml aliquots of growth media were analyzed for alk. phosph. activity using the SEAP fluorogenic assay following the manufacturer's instructions.
Thioglycollate mouse model of inflammation
Male, 6-to 8-week-old (20 g) BALB/c mice, six per group were used. Mice were injected i.p. with either vehicle (200 ml of 1% ethanol in PBS), dexamethasone (Dex, a dose of 2 mg/kg in 200 ml of 1% ethanol in PBS), or an equimolar amount (102 nmol of drug/animal) of DS (5.85 mg/kg in 200 ml of 1% ethanol in PBS). After 30 min, mice were injected i.p. with 1.5 ml of 3% TG in PBS containing 1% ethanol. At 4 h post-TG, the i.p. fluid was collected and neutrophils were counted. All work performed with animals was conducted in compliance with the Animal Welfare Act (CFR 9) and its amendments.
Mouse pulmonary DNA transfer
For studies of in vivo gene delivery, mice (C57/B6) were anesthetized with ketamine/zylazine (i.p.). A total of eight mice per group received 50 ml of lipid/plasmid (100 mg pCB-AP (6075 bp) in 10% sucrose) by nasal instillation during inspiration following the approach of Lee et al. 17 Either DS or DC-Chol (Avanti Polar) was used at a molar ratio of one sterol per base and one cationic lipid per DOPE, resulting in a cationic lipid:DOPE:phosphate molar ratio of 1:1:1. Mice were weighed and euthanized at 1 or 7 days postinstillation. The lung from each mouse was harvested and weighed. One half of each lung was homogenized in 2 ml of 1 Â Reporter Gene Assay Lysis Buffer (Roche Diagnostics) and clarified by centrifugation (10 min, 3000 r.p.m.). Supernatants were stored at À801C until assayed in triplicate using the SEAP Chemiluminescent kit (Roche Diagnostics). Antigenic levels of TNF-a and IFN-g were quantified against mouse standards using ELISA (Pierce Endogen) at Day 1 based on peak inflammatory responses expected at this time. 3 All work performed with animals was conducted in compliance with the Animal Welfare Act (CFR 9) and its amendments.
